Read by QxMD icon Read

cancer associated venous thromboembolic disease

Manabu Sakurai, Koji Matsumoto, Masahiko Gosho, Akiko Sakata, Yoshihiko Hosokawa, Yuri Tenjimbayashi, Takashi Katoh, Ayumi Shikama, Haruna Komiya, Hiroo Michikami, Nobutaka Tasaka, Azusa Akiyama-Abe, Sari Nakao, Hiroyuki Ochi, Mamiko Onuki, Takeo Minaguchi, Hiroyuki Yoshikawa, Toyomi Satoh
OBJECTIVES: Our 2007 study of 32 patients with ovarian cancer reported the possible involvement of tissue factor (TF) in the development of venous thromboembolism (VTE) before treatment, especially in clear cell carcinoma (CCC). This follow-up study further investigated this possibility in a larger cohort. METHODS: We investigated the intensity of TF expression (ITFE) and other variables for associations with VTE using univariate and multivariate analyses in 128 patients with epithelial ovarian cancer initially treated between November 2004 and December 2010, none of whom had received neoadjuvant chemotherapy...
October 17, 2016: International Journal of Gynecological Cancer
Benilde Cosmi
Idiopathic or unprovoked venous thromboembolism is an event occurring in the absence of any apparent provoking or triggering environmental risk factors, such as surgery, trauma, and immobilization. Areas covered: Unprovoked VTE can be associated with occult cancer, but only limited, and not extensive cancer screening, may be warranted, as the rate of occult cancer is low in such patients. Routine thrombophilia testing is not currently recommended as it does not influence the management of the disease. The duration of anticoagulation for unprovoked VTE after the first three months is still debated as the disease tends to recur regardless of treatment duration...
October 14, 2016: Expert Review of Cardiovascular Therapy
Judith S Brand, Elham Hedayati, Nirmala Bhoo-Pathy, Jonas Bergh, Per Hall, Keith Humphreys, Jonas F Ludvigsson, Kamila Czene
BACKGROUND: Venous thromboembolism (VTE) is a serious complication of cancer and its treatment. The current study assessed the risk and clinical predictors of VTE in breast cancer patients by time since diagnosis. METHODS: This Swedish population-based study included 8338 breast cancer patients diagnosed from 2001 to 2008 in the Stockholm-Gotland region with complete follow-up until 2012. Their incidence of VTE was compared with the incidence among 39,013 age-matched reference individuals from the general population...
October 11, 2016: Cancer
Simon Mantha, Eva Laube, Yimei Miao, Debra M Sarasohn, Rekha Parameswaran, Samantha Stefanik, Gagandeep Brar, Patrick Samedy, Jonathan Wills, Stephen Harnicar, Gerald A Soff
Low-molecular weight heparin (LMWH) has been the standard of care for treatment of venous thromboembolism (VTE) in patients with cancer. Rivaroxaban was approved in 2012 for the treatment of pulmonary embolism (PE) and deep vein thrombosis (DVT), but no prior studies have been reported specifically evaluating the efficacy and safety of rivaroxaban for cancer-associated thrombosis (CAT). Under a Quality Assessment Initiative (QAI), we established a Clinical Pathway to guide rivaroxaban use for CAT and now report a validation analysis of our first 200 patients...
September 30, 2016: Journal of Thrombosis and Thrombolysis
Rayko Evstatiev
Iron deficiency, the most common nutritional deficiency worldwide, is often associated with reactive thrombocytosis. Although secondary thrombocytosis is commonly considered to be harmless, there is accumulating evidence that elevated platelet counts, especially in the setting of iron deficiency, can lead to an increased thromboembolic risk in both arterial and venous systems. Here we present the mechanisms of iron deficiency-induced thrombocytosis and summarize its clinical consequences especially in patients with inflammatory bowel diseases, chronic kidney disease or cancer...
October 2016: Wiener Medizinische Wochenschrift
Jorge D Ramos, Martin F Casey, Aristotelis Bamias, Ugo De Giorgi, Joaquim Bellmunt, Lauren C Harshman, Sylvain Ladoire, Yu-Ning Wong, Ajjai S Alva, Jonathan E Rosenberg, Matthew D Galsky, Evan Y Yu
BACKGROUND: The Khorana score is a predictive risk model for venous thromboembolism (VTE) in patients with cancer planning to receive chemotherapy. Urothelial carcinoma and variant histologies (UC/VH) were underrepresented in the model. We sought to evaluate whether the Khorana score predicts for VTE in a retrospective multinational data set of patients with metastatic UC/VH. METHODS: Patients diagnosed with metastatic UC/VH who received chemotherapy were eligible...
September 16, 2016: Clinical and Applied Thrombosis/hemostasis
Bethany T Samuelson, Adam Cuker, Deborah M Siegal, Mark Crowther, David A Garcia
BACKGROUND: The direct oral anticoagulants (DOACs) are the treatment of choice for most patients with atrial fibrillation and/or non-cancer associated venous thromboembolic disease. While routine monitoring of these agents is not required, assessment of anticoagulant effect may be desirable in special situations. The objective of this study was to systematically review and summarize current evidence regarding laboratory assessment of the anticoagulant effects of dabigatran, rivaroxaban, apixaban and edoxaban...
September 13, 2016: Chest
Riccardo Cappato, Robert Welsh
The vast clinical research programme for the direct, oral factor Xa inhibitor rivaroxaban has generated a wealth of data since the first rivaroxaban approval in 2008 for the prevention of venous thromboembolism (VTE) in patients undergoing elective hip or knee replacement surgery. While rivaroxaban is widely used across a spectrum of seven indications, there is continuous commitment to investigating its wider benefits in new indications and attempts to refine current evidence. Key data from recently completed randomised controlled trials (RCTs) have shown that rivaroxaban is a feasible anticoagulation option for patients with non-valvular atrial fibrillation (NVAF) undergoing cardioversion or catheter ablation...
September 28, 2016: Thrombosis and Haemostasis
Christopher S King, Steven D Nathan
Despite the development of pharmacological therapies that are effective in slowing the progression of idiopathic pulmonary fibrosis (IPF), it remains a debilitating and lethal condition. In addition to the adverse effects caused by pulmonary fibrosis, most patients with IPF have associated comorbid conditions, which might negatively affect functional status, quality of life, and survival. Comorbid conditions can be pulmonary or extrapulmonary. Pulmonary comorbidities include pulmonary hypertension, emphysema, and lung cancer, while non-pulmonary conditions include venous thromboembolism, coronary artery disease, congestive heart failure, sleep-disordered breathing, gastro-oesophageal reflux disease, and anxiety or depression...
September 2, 2016: Lancet Respiratory Medicine
P J Vinholt, A M Hvas, H Frederiksen, L Bathum, M K Jørgensen, M Nybo
INTRODUCTION: Platelet count is used to determine bleeding risk and monitoring thrombopoiesis. While abnormal platelet counts are associated with mortality and morbidity, it is unclear whether it also apply to platelet counts within reference range. We investigated the relationship between platelet count (100-450×10(9)/L) and mortality, development of future cardiovascular disease (myocardial infarction, ischaemic stroke, or peripheral vascular disease), venous thromboembolism, bleeding or cancer in the general population...
August 20, 2016: Thrombosis Research
Aida Moeini, Hiroko Machida, Tsuyoshi Takiuchi, Erin A Blake, Marianne S Hom, Toshio Miki, Osamu Matsuo, Koji Matsuo
OBJECTIVE: Recent studies have demonstrated that surgical menopause results in a significantly increased risk of nonalcoholic fatty liver disease (NAFLD) in women with endometrial cancer. In addition, venous thromboembolism (VTE) is known to be one of the major prognostic factors for decreased survival in endometrial cancer. Given the fact that coagulation factors are produced in the liver, the correlation between NAFLD and VTE was examined in endometrial cancer. METHODS: A retrospective study was conducted to examine patients with endometrial cancer who underwent surgical staging including oophorectomy between 2000 and 2013 (n = 714)...
August 31, 2016: Clinical and Applied Thrombosis/hemostasis
Jan Šmrha, Petr Kessler, Hynek Poul, Michaela Harudová
BACKGROUND: The treatment with low-molecular-weight heparin (LMWH) is recommended for patients with cancer associated thrombosis (CAT) during the first 6 months; the initial therapeutic dose can be reduced to 60-75 % after one month. The therapy should be reevaluated after 6 month and subsequent therapy using LMWH or warfarin is recommended indefinitely, unless the cancer is resolved or any major contraindications arise. AIMS: To analyze the usage of various treatment modalities in CAT patients after the initial 6 month period according to the course of cancer...
2016: Vnitr̆ní Lékar̆ství
Syed S Mahmood, Farhad Abtahian, Annemarie E Fogerty, Philip Cefalo, Cheryl MacKay, Michael R Jaff, Ido Weinberg
BACKGROUND: Patients with metastatic carcinoma and venous thromboembolism commonly have contraindications to anticoagulation that prompts use of retrievable inferior vena cava filters. OBJECTIVES: The aim of this study was to compare the pattern of inferior vena cava filter use, anticoagulation management and development of inferior vena cava filter related complications in patients with localized versus metastatic carcinoma. METHODS: We conducted a retrospective cohort study of inferior vena cava filter use at a tertiary referral hospital between January 1, 2009 and December 31, 2011...
July 28, 2016: American Journal of Medicine
Netanel A Horowitz, Noa Lavi, Yona Nadir, Benjamin Brenner
With increase of maternal age, the incidence of haematological malignancies during pregnancy is rising and posing diagnostic and treatment challenges. Lymphoma is the fourth most common malignancy diagnosed in pregnancy; Hodgkin lymphoma is more frequent in pregnant women than non-Hodgkin lymphoma (NHL). The proportion of highly aggressive lymphomas in pregnant women is significantly higher than in non-pregnant women of reproductive age. Reproductive organ involvement is observed in almost half of pregnant women with NHL...
September 27, 2016: Thrombosis and Haemostasis
Sigrid K Braekkan, Scott D Grosse, Ekwutosi M Okoroh, James Tsai, Suzanne C Cannegieter, Inger Anne Naess, Steinar Krokstad, John-Bjarne Hansen, Finn Egil Skjeldestad
BACKGROUND: The burden of venous thromboembolism (VTE) related to permanent work-related disability has never been assessed among a general population. Therefore, we aimed to estimate the risk of work-related disability in subjects with incident VTE compared with those without VTE in a population-based cohort. METHODS: From the Tromsø Study and the Nord-Trøndelag Health Study (HUNT), Norway, 66005 individuals aged 20-65 years were enrolled in 1994-1997 and followed to December 31, 2008...
July 13, 2016: Journal of Thrombosis and Haemostasis: JTH
F J Sherida H Woei-A-Jin, Margot E T Tesselaar, Patrica Garcia Rodriguez, Fred P H T M Romijn, Rogier M Bertina, Susanne Osanto
BACKGROUND: Cancer-related venous thromboembolism (VTE) heralds a poor prognosis, especially in pancreatic adenocarcinoma (PAC). Tissue factor (TF) is implicated as one of the main culprits in PAC-associated VTE and disease progression. METHODS: In a prospective cohort study of 79 PAC patients, we measured plasma CA19-9 and microparticle-associated TF activity (MP-TF activity). In addition, we enumerated TF(+)MPs and MUC1(+)MPs in plasma (n=55), and studied the expression of TF, MUC1, CD31 and CD68 in tumour tissue (n=44)...
July 26, 2016: British Journal of Cancer
Joanna Rupa-Matysek, Lidia Gil, Renata Kroll-Balcerzak, Marta Barańska, Mieczysław Komarnicki
It has been suggested that mean platelet volume (MPV) is associated with the risk of venous thromboembolism (VTE) and increased mortality in patients with cancer. We evaluated the association of MPV with VTE and mortality in patients treated for diffuse large B-cell lymphoma (DLBCL). Retrospective analyses were performed on 184 adult patients (median age 59, 55% men), of whom 141 were newly diagnosed, and 43 had relapse/refractory DLBCL. During the observation period (median 499 days), 39 (21.2%) patients developed VTE...
July 5, 2016: Hematological Oncology
Avradip Santra, Saumen Nandi, Saibal Mondal, Subhankar Chakraborty
Superior vena cava (SVC) syndrome is not an uncommon occurrence in patients with malignancy and it is often described as a medical emergency. In majority of the cases, SVC syndrome occurs due to mechanical obstruction of the SVC by extraluminal compression with primary intrathoracic malignancies. However, intraluminal obstruction due to thrombosis can also produce symptoms and signs of SVC syndrome. Clot-related SVC obstruction is mostly associated with indwelling central venous catheter and pacemaker leads, although such thrombosis can occur spontaneously in a background of a hypercoagulable state, e...
July 2016: Iranian Journal of Medical Sciences
Zbigniew Krasiński, Beata Krasińska, Łukasz Dzieciuchowicz, Tomasz Urbanek, Marcin Gabriel
A close causal relationship between cancer and venous thrombosis gives rise to questions about the effect of treatment modalities, in particular of the administered drugs, in patients with cancer-related venous thrombosis. An increased risk of chemotherapy-associated venous thromboembolism (VTE) has been well documented, while the effect of heparins used in VTE treatment on the disease course and prognosis in cancer patients has not been fully elucidated. This paper discusses the outcomes of the studies conducted so far investigating the role of heparins, in particular, low-molecular-weight heparins (LMWHs), in the prevention of thrombosis in cancer patients...
June 23, 2016: Polskie Archiwum Medycyny Wewnętrznej
Haider Mahdi, Qataralnada Aljebori, David Lockart, Laura Moulton
STUDY OBJECTIVE: To determine the incidence of venous thromboembolism (VTE) after laparoscopic surgery for gynecologic cancer DESIGN: Retrospective analysis of the ACS-NSQIP database DESIGN CLASSIFICATION: Retrospective analysis of a national surgical database SETTING: Academic and community health care institutions across the United States PATIENTS: Women who underwent at least one major laparoscopic surgery for uterine, ovarian and cervical cancers INTERVENTION: Data was collected on surgical procedure, patient demographic variables type of malignancy and VTE and mortality outcomes within 30 days of surgery MEASUREMENTS: VTE was defined as deep venous thrombosis requiring therapy (DVT) and pulmonary embolism (PE) confirmed by imaging or autopsy within 30 days of surgery...
June 21, 2016: Journal of Minimally Invasive Gynecology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"